Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.

Athanassios Argiris,Shuli Li,Panayiotis Savvides,James P Ohr,Jill Gilbert,Marshall A Levine,Arnab Chakravarti,Missak Haigentz,Nabil F Saba,Chukwuemeka V Ikpeazu,Charles J Schneider,Harlan A Pinto,Arlene A Forastiere,Barbara Burtness

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2019）

引用 68|浏览58

暂无评分

摘要

The addition of bevacizumab to chemotherapy did not improve OS but improved the response rate and progression-free survival with increased toxicities. These results encourage biomarker-driven studies of angiogenesis inhibitors with better toxicity profiles in select patients with SCCHN.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要